Metagenomi Therapeutics (MGX) Jefferies Global Healthcare Conference 2026 summary

Strategic vision and program updates

• Transitioning from a CRISPR platform to a therapeutic company, with IND submission for MGX-001 in hemophilia A planned for Q4 this year.

• MGX-001 aims to address limitations of prior gene therapies by enabling durable genomic integration and expression, demonstrated in non-human primate studies.

• Proprietary gene editing platform, distinct from CRISPR-Cas9, offers precise editing, large integration, and broad genome access.

• MGX-001 is designed for all ages, including children, with a mechanism that ensures stable, heritable expression of factor VIII.

• The regulatory path is clear, with a collaborative pre-IND meeting with the FDA and clinical entry targeted for 2027.

Preclinical data and clinical development

• NHP studies show stable factor VIII expression up to 19 months, with no year-over-year loss and favorable safety profile.

• Dose-range-finding studies confirm a clear dose-response and therapeutic window, with no thrombosis observed at highest doses.

• Orthogonal safety assessments revealed no validated off-targets or translocations.

• Phase I/II global study will use dose escalation to establish safety and identify optimal dosing for target factor VIII levels.

• Early clinical readouts are expected within weeks of dosing, with factor VIII activity above 50 IU/dL as the curative benchmark.

Community engagement and feedback

• Strong engagement with patient advocacy and medical communities, reinforcing the urgent need for a curative therapy.

• Community feedback highlights the importance of normal, durable factor VIII levels and supports the unique mechanism of MGX-001.

• Encouragement to treat pediatric patients early due to the therapy’s potential for endogenous expression during liver growth.

• Ongoing data publication and engagement planned throughout the year.